Αρχειοθήκη ιστολογίου

Πέμπτη 20 Ιουλίου 2017

Nintedanib in ovarian cancer.

This article reviews the preclinical and clinical efficacy of nintedanib in ovarian cancer, its pharmacokinetic and pharmacodynamics profile, safety issues, together with an overview of clinical trials carried out so far. A literature search was made in PubMed for nintedanib, ovarian cancer, angiogenesis, and on ClinicalTrials.gov site for clinical trials with nintedanib. Expert opinion: An ongoing phase III trial investigating nintedanib combined with first-line chemotherapy in ovarian cancer has shown a statistically significant progression free survival benefit, although there were toxicity issues. The true clinical benefit of nintedanib in ovarian cancer including its optimal treatment setting and dosage still need to be addressed. PMID: 28721753 [PubMed - as supplied by publisher]...

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uEg0Px
via IFTTT

στις

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Εγγραφή σε: Σχόλια ανάρτησης (Atom)

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Φόρτωση...